# T-CELL RECRUITMENT ENGINEERING: DOCTRINE STATUS

**Last Updated:** October 2024  
**Partner:** Dr. Kristen Pauken, MD Anderson Cancer Center  
**Status:** ðŸŸ¢ **PARTNERSHIP-READY**

---

## **QUICK SUMMARY**

**The Discovery:** Dr. Pauken invented IV antibody "timestamp" toolâ€”tracks T-cell recruitment in real-time. Proved anti-PD-1 DOUBLES fresh T-cell recruitment (not just "waking up" exhausted cells). Problem: 70% of tumors have collapsed recruitmentâ€”don't know WHY.

**Our Solution:** Diagnose bottleneck (RNA-seq â†’ Type A/B/C/D), design precision rescue (4 different interventions), predict who responds to PD-1 blockade.

**The Pilot:** 8 weeks, $0 cost, 30 tumors (RNA-seq + timestamp data). Test if bulk RNA predicts bottleneck (target: r > 0.60). Design interventions. Co-author publications.

---

## **DOCUMENT ECOSYSTEM**

### **1. Main Doctrine (`tcell.mdc`)** - 753 lines
- **Purpose:** Complete technical education (18-min read)
- **Content:** Dr. Pauken's findings, recruitment biology, bottleneck classification, 4 intervention designs, APIs, usage guide
- **Audience:** Internal team, technical partners, immunology researchers
- **Status:** âœ… Complete

### **2. Partnership Blueprint (`TCELL_MD_ANDERSON_PARTNERSHIP.mdc`)** - 471 lines
- **Purpose:** Executive positioning for MD Anderson leadership
- **Content:** Value proposition, 8-week pilot details, IP terms, stakeholder messaging, objection handling
- **Audience:** MD Anderson Leadership, Dr. Pauken Lab, Clinical Trial PIs
- **Status:** âœ… Complete

### **3. Intel Source (`intel.mdc`)** - 67 lines
- **Purpose:** Raw presentation notes from Dr. Pauken's talk
- **Content:** Transcript summary, core findings, unanswered questions
- **Audience:** Internal reference
- **Status:** ðŸŸ¡ Needs Part II update (replace hypothetical with refined positioning)

---

## **KEY FINDINGS (DR. PAUKEN'S DATA)**

**âœ… Validated:**
1. IV antibody timestamp tool works (distinguishes fresh recruits from residents)
2. Fresh recruits are less exhausted (LOW PD-1/TIM-3/LAG-3)
3. Recruitment collapses over time (Day 10 HIGH â†’ Day 25 LOW)
4. Anti-PD-1 doubles recruitment (primary mechanism = logistics, not exhaustion reversal)
5. Same highways for cancer & autoimmunity (PD-1 worsens checkpoint-induced diabetes)

---

## **OUR SOLUTION (3 WEAPONS)**

### **Weapon #1: Recruitment Collapse Diagnostic**
- **What:** RNA-seq â†’ identify bottleneck (Type A: Chemokine, B: Barrier, C: Suppressor, D: Vascular)
- **Status:** âœ… Operational (design tools ready)
- **Confidence:** âš ï¸ MEDIUM (needs validation; literature baseline r = 0.3-0.5)
- **API:** `/api/recruitment/diagnose_bottleneck`

### **Weapon #2: Precision Intervention Designs**
- **Type A (Chemokine Desert):** CXCL9/CXCL10/CCL5 overexpression cassette
- **Type B (Physical Barrier):** CRISPRi (FAP/COL1A1) + MMP overexpression
- **Type C (Suppressor):** Anti-TGFÎ²/VEGF bispecific OR CRISPRi
- **Type D (Vascular):** VEGF normalization + ANGPT1
- **Status:** âœ… Operational (design tools validated)
- **Confidence:** âœ… HIGH (Evo2, CRISPRi operational)
- **APIs:** `/api/design/generate_chemokine_cassette`, `/api/design/generate_stromal_cassette`, etc.

### **Weapon #3: Autoimmunity Blocker**
- **What:** Selective recruitment inhibitor (block pancreas WITHOUT blocking tumor)
- **Status:** ðŸ”´ Pre-clinical (requires NOD data)
- **Confidence:** ðŸ”´ LOW (untested hypothesis)
- **API:** `/api/design/generate_autoimmunity_blocker`

---

## **8-WEEK PILOT STRUCTURE**

**Input:** 20-30 mouse tumors (HIGH vs LOW recruitment) with RNA-seq + timestamp flow data

**Week 1-2:** Data transfer, QC, feature extraction  
**Week 3-4:** Correlation analysis, bottleneck classifier training (TEST: r > 0.60?)  
**Week 5-6:** Design 5 interventions (one per bottleneck + combination)  
**Week 7-8:** Deliverables package (heatmap, designs, validation protocol, calibration report)

**Deliverables:**
1. Bottleneck heatmap for all 30 tumors
2. Gene signature (top 20 genes predicting recruitment collapse)
3. Anti-PD-1 response predictor (baseline biomarker)
4. 5 intervention designs with validation protocols
5. Calibration report (r-value, performance metrics)

**Success:** r > 0.60 â†’ HIGH confidence  
**Partial:** r = 0.50-0.60 â†’ recommend spatial RNA-seq  
**Pivot:** r < 0.50 â†’ document why, partner keeps all code

---

## **CONFIDENCE ASSESSMENT**

| **Capability** | **Status** | **Confidence** | **Why** |
|---------------|----------|---------------|---------|
| Design chemokine cassettes | âœ… Operational | âœ… HIGH | Evo2 validated, CRISPRi operational |
| Design stromal remodelers | âœ… Operational | âš ï¸ MEDIUM | MMP safety requires testing |
| Design suppressor neutralizers | âœ… Operational | âœ… HIGH | Antibody design validated |
| Design vascular normalizers | âœ… Operational | âš ï¸ MEDIUM | VEGF dosing tricky |
| RNA-seq â†’ bottleneck prediction | âœ… Operational | âš ï¸ MEDIUM | Similar to TLS problem (r = 0.3-0.5 lit baseline) |
| Autoimmunity blocker | ðŸ”´ Pre-clinical | ðŸ”´ LOW | Requires NOD data, untested |

---

## **BUSINESS MODEL**

**Market:** $50B checkpoint inhibitor market, 70% failure rate = $35B addressable

**Revenue Streams:**
1. **Diagnostic Tool:** $500/sample or $50K institutional license (bottleneck classifier)
2. **Intervention IP:** 3-5% royalty on licensed products (recruitment enhancers)
3. **Autoimmunity Blocker:** 3-5% royalty (checkpoint safety product)

**Competitive Moat:**
- Timestamp data advantage (no one else has this)
- Multi-modal approach (4 solutions, not one-size-fits-all)
- Learning system (partner data trains proprietary models)

---

## **FAILURE MODES & PIVOTS**

**Scenario A: RNA r < 0.50**
- **Pivot:** Recommend spatial RNA-seq, re-train classifier
- **Deliverable:** Intervention designs still useful

**Scenario B: Multiple bottlenecks per tumor**
- **Pivot:** Design combination cassettes
- **Timeline:** +2-4 weeks

**Scenario C: Bottleneck rescue fails**
- **Pivot:** Identify non-druggable bottlenecks
- **Deliverable:** Stratification tool (who WON'T respond)

**Scenario D: All assumptions correct**
- **Outcome:** Validate all weapons, co-author Nature papers, clinical translation

---

## **NEXT ACTIONS**

**Immediate:**
1. Schedule 60-min call with Dr. Pauken lab
2. Finalize pilot protocol (which 30 tumors, data format)
3. Execute Data Sharing Agreement

**3-Month:**
1. Complete 8-week pilot
2. Validate intervention designs (measure IV+ influx)
3. Co-author manuscript (bottleneck classification)

**6-12 Month:**
1. Clinical trial integration (bottleneck classifier as biomarker)
2. IND planning (combination product)
3. Autoimmunity blocker validation (if NOD data available)

---

**DOCTRINE STATUS:** ðŸŸ¢ **COMPLETE & PARTNER-READY**  
**CONFIDENCE:** âš ï¸ **MEDIUM** (awaiting validation data to move to HIGH)  
**NEXT MILESTONE:** 8-week pilot execution with MD Anderson
